A Swiss-Japanese alliance that has thrived in the crisis

by
Swissinfo
My articles My booksMy videos
Follow on:TwitterFacebookGoogle +

Roche’s HQ, overlooking the Rhine river in Basel. Keystone / Georgios Kefalas

It was the start of one of the most unusual cross-cultural marriages when Roche bought a controlling stake in Chugai Pharmaceutical for $1.4bn back in 2002, promising arm’s length management.

In the course of the 18 months of negotiations it took to reach a deal, Chugai, a Japanese pioneer in biotechnology, presented a single sheet of paper with a list of conditions it would not budge on, the main ones being management autonomy and the continued listing of its shares in Tokyo.

If anyone described the deal as a merger, Chugai, with annual revenue less than a tenth of its Swiss parent, quietly corrected this to “strategic alliance”, but few took those words at face value.

Nearly two decades later, the partnership has not only survived but has prospered during the coronavirus crisis, with the two companies now trialling their rheumatoid arthritis drug Actemra as a potential treatment for people who are critically ill with Covid-19.

With investors pinning their hopes on the drug, Chugai passed a new milestone this week, replacing Sony as Japan’s fifth most valuable company as its shares hit another all-time record. The stock has risen more than 70 per cent since the start of the year, adding $40bn to its market capitalisation. Roche has added nearly $30bn.

The success of the Roche-Chugai partnership stands out in an industry where deals at far bigger prices — such as Johnson & Johnson’s $30bn purchase of Swiss biotech group Actelion in 2017 — have struggled to impress investors, but also because cross-border deals are particularly challenging in Japan. Companies can be resistant to foreign ownership and their natural instinct is to imagine themselves as buyer rather than bought.

Many alliances, even long-enduring ones such as that between Nissan and Renault, have faltered when faced with pressures such as a full merger, deeper technology transfer or, naturally, testing times of flagging financial performance.

Chugai says it had its own merger scare in August 2014. According to Tatsuro Kosaka, chief executive, that summer still brings back bitter memories of a panicked midnight call at a hot springs resort, informing him of media reports that Roche was set to offer $10bn to take full control. Cutting his holiday short, he drove back to company headquarters in Tokyo the next day.

Regardless of Roche’s intentions at the time, Mr Kosaka insists no talks about any such deal took place. He also rules out a full merger in the future.

Instead, Roche has its 60 per cent stake and three executives on Chugai’s nine-member board, but continues its hands-off approach. There is no one from the Swiss parent, for example, in the senior management team.

This type of alliance is now being touted as a model for cross-border deals, but autonomy does have a cost. Chugai needs to keep on developing innovative drugs — not just to boost the financial performance of both companies but also to maintain trust within Roche that it can leave its Japanese business alone.

So far the relationship has worked well. Chugai has delivered three key drugs — Actemra, haemophilia blockbuster Hemlibra, and lung cancer drug Alecensa — that have made a meaningful contribution to Roche’s global sales. At Chugai, sales have tripled and profits have increased more than 10-fold in the past 18 years, thanks in large part to Roche’s global sales network.

Royalty fees from the Swiss parent have also allowed the Japanese company to focus on decades of costly research it would not have been able to afford if it had gone it alone.

Actemra may be in the global spotlight now but Japan’s first monoclonal antibody drug was created with Osaka University after 20 years of research dating back to the 1980s. When it was first approved by Japanese authorities in 2005, it was to treat the rare Castleman disease before it was launched a few years later to treat rheumatoid arthritis.

During the current crisis, the Roche-Chugai alliance will be able to make use of combined manufacturing resources to ensure it can meet global demand for Actemra, depending on trial results. In addition to Chugai’s plant in Japan, special permission has been granted for Roche unit Genentech’s site in Oregon to undertake part of the drug production process.

The alliance has had a huge boost this year because of the hopes for Actemra, but investor enthusiasm is likely to wane without firm scientific proof of its effectiveness against Covid-19. And in the longer term, success will hinge more on whether Chugai can deliver another blockbuster.

The case of Nissan and Renault, although in a different industry, shows trust built over decades can abruptly collapse especially when a relationship is tied to certain individuals. But the Roche-Chugai alliance certainly provides useful lessons in these uncertain times for what it might take to keep a cross-border relationship intact.

Copyright The Financial Times Limited 2020

You Might Also Like

Coronavirus: cheap drug substantially cuts severe case death risk, according to large UK trial

A trial at Oxford University suggests an existing low cost drug can cut the risk of death from Covid-19 substantially. Tests involving 6,000 hospitalised Covid-19 patients suggest the drug can cut the risk of death for those on ventilators from 40% to 28%. For patients needing oxygen the risk of death could be cut from 25% to 20%.

Coronavirus: the rising number of mild cases with symptoms lasting months

Those with mild Covid-19 symptoms are supposed to recover after two weeks. However, a rising number of relatively young people with mild cases report symptoms months later. Johns Hopkins Medicine says that those with mild cases of COVID-19 appear to recover within one to two weeks. For severe cases, recovery may take six weeks or more.

Coronavirus: national lockdown not part of Switzerland’s second wave response plan

Switzerland’s federal government is against imposing nationwide restrictions to slow the spread of a second wave on infections, according to the NZZ am Sonntag newspaper. The federal government plan, which is under development, is more regional than the response to the first wave of infections and focuses decision making power at the cantonal level, reported the newspaper.

Coronavirus: latest antibody study suggests 10.8 percent of Geneva infected in first wave

A recently published update to the ongoing study in Geneva to assess the extent of SARS-CoV-2 infection suggests 10.8% of the population may have been infected in the first wave of infections. The study, which tests a sample of the population over time for IgG SARS-CoV-2 antibodies, started in early April 2020. The latest figures come from the fifth week of testing, which was concluded on 9 May 2020. 

Coronavirus: Swiss authorities not open enough in early weeks, says medical expert

The Swiss authorities should have been more open about what they did and didn’t know about the SARS-CoV-2 virus in the early stages, according to Bertrand Kiefer, doctor, ethicist and editor of the Swiss Medical Review.

‘We will come through this together’

The upheaval caused by the coronavirus, Covid-19, is all around us. And I know many are anxious, worried and confused. That’s absolutely natural. We are facing a health threat unlike any other in our lifetimes. Meanwhile, the virus is spreading, the danger is growing, and our health systems, economies and day-to-day lives are being severely tested.

Finance minister Ueli Maurer eyes central bank surplus to reduce expected debts

Swiss Finance Minister Ueli Maurer wants the country’s central bank to contribute to the reduction of the debt caused by the coronavirus pandemic. “I suggest the Swiss National Bank spends the money from an annual surplus to reduce coronavirus-related debts,” he told the Neue Zürcher Zeitung newspaper on Wednesday.

100 Swiss watch brands risk extinction due to coronavirus, expert says

The coronavirus crisis could eliminate up to 100 Swiss watch brands from the market, according to an expert interviewed by the German-language weekly NZZamSonntag. Production came to a standstill during the pandemic and the most important export markets collapsed. Whether tourists with purchasing power will return to Switzerland remains in question. The watch industry, notes the newspaper, has been “caught in the perfect storm”.